SCHEMBL3010490

SCHEMBL3010490

O=S(=O)(c1cc(Cl)cc(Cl)c1)N1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
SLC13A5 Q86YT5 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GBA1 P04062 1/20 0.43
CNR1 P21554 5/20 0.42
LSS P48449 2/20 0.42
MAPT P10636 2/20 0.41
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 2/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019973 0.93 THRB (0.47) POLBSMN1; SMN2ALDH1A1L3MBTL1GBA1
SCHEMBL3018162 0.93 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1L3MBTL1GBA1CNR1
SCHEMBL3013183 0.93 CNR1 (0.51) SMN1; SMN2ALDH1A1L3MBTL1GBA1CNR1
SCHEMBL3007845 0.92 ALDH1A1 (0.43) POLBSLC13A5SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3007797 0.92 SMN1; SMN2 (0.51) POLBSMN1; SMN2ALDH1A1L3MBTL1LSS
SCHEMBL3001163 0.92 THRB (0.43) POLBSLC13A5SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3018905 0.91 POLB (0.49) POLBSMN1; SMN2ALDH1A1L3MBTL1GBA1
SCHEMBL3016473 0.91 CNR1 (0.43) POLBSMN1; SMN2ALDH1A1L3MBTL1GBA1
SCHEMBL3018692 0.91 ALDH1A1 (0.48) POLBSMN1; SMN2ALDH1A1L3MBTL1GBA1
SCHEMBL3003684 0.90 LMNA (0.47) POLBSMN1; SMN2ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885SLC13A5 2179/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.